Dynavax Technologies (DVAX) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2681582019
Dynavax Technologies Corporation, traded as NASDAQ:DVAX, is a biopharmaceutical company in the commercial stage, with a primary focus on developing and bringing vaccines to the market in the United States.
One of its flagship products is HEPLISAV-B, a vaccine for hepatitis B that covers all known strains of the virus in individuals aged 18 years and above, available in both the United States and Europe. Additionally, Dynavax manufactures and sells CpG 1018, an adjuvant integral to HEPLISAV-B's efficacy.
Aside from its products, Dynavax Technologies Corporation has established collaborative agreements with various entities such as Valneva Scotland Limited, Zhejiang Clover Biopharmaceuticals, Inc., and several others, expanding its reach and capabilities in the biopharmaceutical industry.
Originally known as Double Helix Corporation, Dynavax Technologies Corporation has been in operation since 1996, with its headquarters situated in Emeryville, California. For more information, visit their website at https://www.dynavax.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
DVAX Stock Overview
Market Cap in USD | 1,544m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2004-02-19 |
DVAX Stock Ratings
Growth 5y | 3.04 |
Fundamental | -0.04 |
Dividend | - |
Rel. Performance vs Sector | 0.14 |
Analysts | 4.40/5 |
Fair Price Momentum | 12.74 USD |
Fair Price DCF | 20.61 USD |
DVAX Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
DVAX Growth Ratios
Growth 12m | 4.17% |
Growth Correlation 12m | -17% |
Growth Correlation 3m | -65% |
CAGR 5y | 10.58% |
Sharpe Ratio 12m | -0.04 |
Alpha vs SP500 12m | -22.92 |
Beta vs SP500 5y weekly | 1.07 |
ValueRay RSI | 53.53 |
Volatility GJR Garch 1y | 29.92% |
Price / SMA 50 | -3.29% |
Price / SMA 200 | -12.65% |
Current Volume | 1817.4k |
Average Volume 20d | 2154.4k |
External Links for DVAX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 04, 2024, the stock is trading at USD 11.74 with a total of 1,817,398 shares traded.
Over the past week, the price has changed by +4.73%, over one month by -3.69%, over three months by -7.92% and over the past year by +6.53%.
According to ValueRays Forecast Model, DVAX Dynavax Technologies will be worth about 14.1 in May 2025. The stock is currently trading at 11.74. This means that the stock has a potential upside of +20.27%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 25.8 | 119 |
Analysts Target Price | 24.5 | 109 |
ValueRay Target Price | 14.1 | 20.3 |